Replies to Post #3812 onElectromedical Technologies Inc (EMED)

Play Episode

3min

Proactive - Interviews for investors

Nevis Brands doubles revenue in 2024, cuts losses & expands in key Markets

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to discuss the company’s financial results for fiscal year 2024 and the fourth quarter ending November 30, 2024. Nevis reported $1.56 million in revenue, more than doubling its 2023 sales as it expanded into new markets and introduced new cannabis products. The company narrowed its net loss to approximately $362,000, down from $400,000 the previous year. When excluding interest, depreciation, and amortization, the adjusted loss was reduced to about $58,000. Nevis maintained its leading position in Washington’s cannabis beverage market and achieved the second-best sales ranking in Missouri within its first year in that state. The company also made significant progress in debt reduction, cutting current liabilities from $1.12 million to about $573,000 through debt payments and restructuring. Looking ahead to 2025, Nevis expects continued growth driven by expanding sales of its Happy Apple and Major brands in the hemp-derived THC beverage market. The company also looking for market re-entry in Ohio and Arizona following previous licensing and market shifts. All this happening while the company focused on licensing established products in key markets. Kueber acknowledged that the fourth quarter was challenging, with revenue declines due to licensing and market shifts in Arizona, Ohio, Oregon, and California. However, growth in New Jersey and Missouri helped offset these declines, and the company remains focused on long-term expansion and profitability. #proactiveinvestors #nevisbrandsinc #cse #nevi #otcqb #nevif #majorbrand #cannabis #CannabisInvesting #THCDrinks #HappyApple #CannabisStocks #HempTHC #CannabisBeverages #InvestorUpdate #JohnKueber #CannabisNews #CannabisRevenue #DebtReduction #ProactiveInvestors

Proactive - Interviews for investors

ACG Metals CFO says hold hedge strategy is already paying off

ACG Metals Ltd chief financial officer Patrick Henze talked with Proactive's Stephen Gunnion about the company’s recently announced gold hedging strategy and its importance during ACG’s transition phase from precious to base metals. Henze explained that while ACG Metals is ultimately targeting copper production from its Gediktepe mine in Turkey by 2026, the mine currently generates strong cash flow from gold and silver. The company has moved to hedge 50% of its gold production at US$2,875 per ounce through January 2026, helping secure revenue in a volatile pricing environment. He noted: “We are currently producing gold and silver, which is a perfect transition for us to become a copper producer in ’26… we can benefit and protect a bit the cash flows by hedging the gold.” The hedge program, executed with Alpha, involves no cash outlay and allows ACG to retain upside exposure above US$3,065 per ounce on the hedged portion. Henze emphasised this strategy helps ACG provide more certainty to bondholders and equity investors by de-risking key financial metrics for 2025. The company remains unhedged on silver and copper, maintaining exposure for future upside. For more updates, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future content. #ACGMetals #GoldHedging #CopperTransition #GediktepeMine #MiningStrategy #GoldPrices #Commodities #CashFlowManagement #MiningInvestment #ProactiveInvestors

Proactive - Interviews for investors

Time Finance CEO on Q3 update: record lending & growth to resilient small businesses

Time Finance PLC (AIM:TIME) CEO Ed Rimmer takes Proactive's Stephen Gunnion through the company’s performance in the third quarter, highlighting a record gross lending book and improved arrears management. Rimmer explained that Time Finance provides funding solutions to small businesses, including invoice finance, asset finance, and secured loans, typically supporting businesses with turnover up to £10 million. He said, “We help businesses grow, but we also help businesses to survive as well.” The company’s lending book reached a record £210 million at the end of February, with arrears falling to 5% from 6% a year earlier. Rimmer noted this progress came despite challenging market conditions and was achieved without compromising credit quality. Margins have also increased, with profit margins now at 40%. This was attributed to tight cost control and improved efficiency, including leveraging technology and streamlining internal processes. Time Finance has not increased its headcount significantly post-COVID, which has helped support margin growth. Rimmer also addressed the broader economic environment, pointing to interest rate pressures, inflation, and increased insolvencies, but emphasised that small businesses remain resilient. The company sees opportunity as traditional banks become more risk-averse, creating space for independent lenders. Visit Proactive’s YouTube channel for more interviews like this. Don’t forget to like the video, subscribe to the channel, and enable notifications so you never miss an update. #TimeFinance #SMElending #AlternativeFinance #BusinessLoans #InvoiceFinance #AssetFinance #Q3TradingUpdate #IndependentLender #FinancialResults #SmallBusinessFinance

Proactive - Interviews for investors

Candel Therapeutics shares positive survival data for investigational immunotherapy in NSCLC

Candel Therapeutics CEO Dr. Paul Peter Tak joined Steve Darling from Proactive to announce final survival data from a Phase 2a clinical trial evaluating the company’s investigational immunotherapy in patients with stage III/IV non-small cell lung cancer (NSCLC) who had an inadequate response to immune checkpoint inhibitor (ICI) treatment. The study reported a median overall survival (mOS) of 24.5 months in 46 evaluable patients who received two courses of the investigational therapy. In a subset of patients who had progressive disease at baseline despite ICI treatment, mOS was 21.5 months. Historically, similar patients receiving standard-of-care chemotherapy have had mOS between 9.8 and 11.8 months, with published studies rarely exceeding 12 months. With a median follow-up of 32.4 months, the data demonstrated long-term survival benefits, with 37% of patients who had progressive disease despite ICI therapy still alive two years after treatment. Based on these positive results, Candel Therapeutics will continue advancing the development program, including preparations for a potential registrational trial in patients with non-squamous histology NSCLC. The U.S. Food and Drug Administration (FDA) has previously granted Fast Track Designation for the investigational therapy in combination with an antiviral agent and ICI therapy for patients with stage III/IV NSCLC who are resistant to first-line PD-(L)1 inhibitors and do not have activating molecular driver mutations or have progressed on targeted therapy. These findings support the therapy’s potential as a new treatment option for NSCLC patients with limited alternatives. #proactiveinvestors #candeltherapeuticsinc #nasdaq #cadl #CancerTreatment #ViralTherapy #ProstateCancer #PancreaticCancer #Glioblastoma #PaulPeterTak #ClinicalTrials #BiotechNews #Immunotherapy #Oncology #CancerResearch

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free